相关实验视频

Updated: Jul 26, 2025

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Monitoring PD-1-Blocking Antibodies Bound to T Cells Derived from a Drop of Peripheral Blood

Published on: February 5, 2020

瑞拉利马布-尼沃卢马布:皮肤科医生的实用概述

Nikita Mullick¹, Vinod E Nambudiri¹

¹Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.

Journal of the American Academy of Dermatology

|June 21, 2023

概括

雷拉利马布加尼沃卢马布是经批准的第一线治疗转移性黑色素瘤的药物. 这种组合疗法为患有不可切除或转移性黑色素瘤的患者提供了双重免疫检查点抑制策略.

科学领域:

免疫治疗是一种免疫疗法.
在瘤学瘤学.
皮肤病学皮肤病学

背景情况:

雷拉利马布是一种针对淋巴细胞激活基因3 (LAG-3) 的新型抗体.
它被批准与编程细胞死亡蛋白1 (PD-1) 抑制剂nivolumab结合使用.
这种组合针对癌症治疗的两个关键免疫检查点.

研究的目的:

审查有关relatlimab-nivolumab的疗效和治疗用途的临床文献.
总结作用机制,临床疗效和安全性概况.
突出正在进行的临床试验和正在积极调查的领域.

主要方法:

对最近出版的文献评论.
对临床试验数据的分析.
免疫检查点抑制机制的概述.

主要成果:

雷拉利马布-尼沃卢马布在转移性黑色素瘤中显示出有效性.
这种组合提供了双重检查点封锁.
组合的安全概况已经确定.

结论:

瑞拉利马布-尼沃卢马布是一种经批准的第一线双检查点抑制剂,用于转移性黑色素瘤.
这一评论为皮肤科医生提供了关于其适当临床用途的信息.
它代表了黑色素瘤治疗的重大进步.

关键词:

BMS-986213 这是一个很好的方法.现场行动组-3 皮肤瘤学皮肤瘤学免疫检查点抑制剂免疫检查点抑制剂发生转移的黑色素瘤.这就是尼沃卢马布 (nivolumab).有关可能的关系.有针对性的治疗.

更多相关视频

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Skin Cancer

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...